Related references
Note: Only part of the references are listed.Prognostic value of tumour-infiltrating CD8+lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Julia Schollbach et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives
Julien Taieb et al.
CANCER TREATMENT REVIEWS (2019)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'
George C. Prendergast et al.
TRENDS IN CANCER (2018)
The TNM classification of malignant tumours-towards common understanding and reasonable expectations
Brian O'Sullivan et al.
LANCET ONCOLOGY (2017)
Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer
Carlos Carvalho et al.
LANCET ONCOLOGY (2017)
S3-Guideline - Colorectal Cancer
Wolff Schmiegel et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2017)
Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
Anne J. Breugom et al.
LANCET ONCOLOGY (2015)
Indoleamine 2,3-dioxygenase vaccination
Mads Hald Andersen et al.
ONCOIMMUNOLOGY (2015)
Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Trine Zeeberg Iversen et al.
CLINICAL CANCER RESEARCH (2014)
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials
Hans-Joachim Schmoll et al.
LANCET ONCOLOGY (2014)
Trial watch: IDO inhibitors in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Has the new TNM classification for colorectal cancer improved care?
Iris D. Nagtegaal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Rikke Baek Sorensen et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
Bernhard Mlecnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
Rikke Baek Sorensen et al.
PLOS ONE (2009)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Alexander J. Muller et al.
NATURE REVIEWS CANCER (2006)